Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 12/20 | 0.45 |
| ▸ | FLT1 | P17948 | 12/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594364 | 0.89 | EGLN1 (0.52) | MEN1ALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL3605396 | 0.86 | KDR (0.54) | RAF1KDRFLT1MEN1KMT2A | |
| SCHEMBL3670190 | 0.83 | HIF1A (0.48) | RAF1KDRFLT1ALDH1A1TYK2 | |
| SCHEMBL3587532 | 0.80 | HIF1A (0.46) | KDRFLT1MEN1ALDH1A1HPGD | |
| SCHEMBL3602119 | 0.79 | KDR (0.49) | RAF1KDRFLT1MEN1KMT2A | |
| SCHEMBL3589610 | 0.79 | RAF1 (0.53) | RAF1KDRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13408251 | 0.77 | ADRB2 (0.56) | MEN1ALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL16628086 | 0.74 | KDR (0.68) | RAF1KDRFLT1MEN1KMT2A | |
| SCHEMBL6030809 | 0.74 | KDR (0.58) | KDRFLT1MEN1ALDH1A1HPGD | |
| SCHEMBL3594043 | 0.74 | RAF1 (0.53) | RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885KDR 843/4885FLT1 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.